1. 1
THE PERSONALIZED
MEDICATION MANAGEMENT
PLATFORM
The Patient & You: Aligning Interests To
Increase Medication Adherence
By: Jon Michaeli EVP
Marketing & Business Development
For:

2. 2
WHAT DRIVES US

3. 3
Founded
August 2012
Launched
Nov 2012 (alpha)
May 2013 (beta)
First Funding
August 2013
Series A
January 2015
FIRST INSPIRATION & MILESTONES

4. 4
PATIENT-CENTRIC PERSONALIZED MEDICATION MANAGEMENT PLATFORM
ADDRESSING ALL MAJOR CAUSES OF NON-ADHERENCE:
Source: Cramer JA, Spilker B, eds. Patient compliance in medical practice and clinical trials. New York: Raven Press,
1991:387-92
Forgetfulness (30%)
Decision to omit doses (11%)
Emotional distress /
Lack of support (7%)
Lack of information /
Information overload (9%)
Low engagement /
Other reasons (27%)
Other priorities /
Medication costs (16%)
WHAT IS MEDISAFE?

5. Quality of Care
5
146M
Prescribed daily meds
700,000
Over/under dose
emergencies
Non-adherence
related deaths
$187B
Lost sales to pharma(cies)
$300B
Related to non-
adherence
Lost RevenuesHealthcare Costs
Sources: CVS research, 2012; CDC research, 2012; Congress report regarding non-adherence, 2012; CapGemini/HealthPrize research 2012
4 minEvery
Statistics are yearly figures (U.S)
WHAT WE’RE UP AGAINST

6. PharmaProvider / Payer / Employer
Pharmacy
Rx and Treatment
Rx Transfers / Refills
Targeted Education
AnalyticsE-Prescription, Pt. History
Pop Health, Cost Savings
Med List, Rx Coverage
Adherence Data & Biometrics
UP TO THE CHALLENGE
Doctor / Care TeamPatient / Caregiver
6
6

7. Dr. Appointments
Social Support
Patient Education - Multimedia
Telemedicine
Intrinsic Reward System
Supportive Content
Positive Reinforcement
Financial Assistance
DEMO / DATA DRIVEN FEED

8. 8
YOUR MEDS
ON YOUR
WATCH

9. -
500,000
1,000,000
1,500,000
2,000,000
2,500,000
2013-Qtr3 2013-Qtr4 2014-Qtr1 2014-Qtr2 2014-Qtr3 2014-Qtr4 2015-Qtr1 2015-Qtr2 2015-Qtr3 2015-Qtr4
9
2.7mm registered users
110K+ app store reviews, 4.5 stars
USER GROWTH & VALIDATION

10. 10
DATA AT SCALE
-
50,000,000
100,000,000
150,000,000
200,000,000
250,000,000
300,000,000
2013-Q3 2013-Q4 2014-Q1 2014-Q2 2014-Q3 2014-Q4 2015-Q1 2015-Q2 2015-Q3 2015-Q4*
330mm doses taken correctly
60mm user sessions / mo.

11. 11
TOP 20 THERAPEUTIC AREAS
12%
4%
3%
0% 5% 10% 15% 20% 25%
Depression / Anxiety
Hypertension
Vitamin
Pain
Diabetes
Antibiotic
Seizures
High Cholesterol
Acid reduction
Hypothyroidism
Anticoagulants
Allergy
Other mental disorders
Asthma
Contraceptive
ADHD
Cancer
Epilepsy
Insomnia
Anti Inflammatory

12. 12
CLINICAL SIGNIFICANCE
Independent
comparative
study of 100
medication
management
apps.
Internal blood
pressure study of
Stage 1 and 2
hypertension
patients after
tracking their BP in
Medisafe.
Retrospective
study using RX fill
data to assess
adherence vs.
control in
hyperlipidemia,
hypertension and
diabetes.
Randomized
Control Trial with
Partners Healthcare
and Evidation Health.
Result:
Medisafe
ranked #1
Result:
19.3mmHg systolic
decline in 30 days
Result:
+8 - 20% adherence
for 3 – 6 months
Result:
Due Q4 2016

13. 13
• Safeguards
• HIPAA compliant
• Bank level security (ISO 27001)
• Medication pre-population
• Import via medical record for ~60% of
covered lives
• Streamlined UI / reduce friction
• Enhanced personalization
• Medication reconciliation
BEYOND THE PATIENT – PHASE 1

14. 14
BEYOND THE PATIENT – PHASE 2
36%
36%
35%
34%
30%
57%
47%
48%
51%
41%
0% 10% 20% 30% 40% 50% 60%
Has empathetic medical and admin staff
Scheduling appts is quick and easy
Communicates test results in timely manner
Takes time to understand my opinions and needs
Allows me to see the doctor I want, when I want
% of consumer who believe providers are dlivering % of providers who believe they're delivering
Source: Patient Experience” it’s Time to Rethink the Consumer Healthcare Journey, GE Healthcare Camden Group, March 2016

15. 15
Despite studies and a bevy of evidence from other investigators
in the field, I still get routinely reminded, when I am out
presenting on connected health, that “physicians don’t want
this data.” This is a resounding theme that ranks right up there
with concerns about liability and reimbursement.
Dr. Joe Kvedar, MD - Center for Connected Health, Partners Healthcare
Feb 25, 2016
BEYOND THE PATIENT – PHASE 2
Source: MedCity News, Feb 25, 2016

16. 16
BEYOND THE PATIENT – PHASE 2
48%
of non-health app users would use them
if recommended by doctors
Source: Technology Advice, 2014

17. 17
BEYOND THE PATIENT – PHASE 2
150 Physicians
Cardiology
Endocrinology
Pain medicine
Psychiatry
Pulmonology
200 Consumers
Chronic pain
Depression/Anxiety
Diabetes Mellitus
Gastrointestinal disorders
Hyperlipidemia
Hypertension
Hypothyroidism

18. 18
How do you monitor patient adherence?
Don’t monitor (21%)
Monitors via email/phone (21%)
Monitors via refills (40%) Patient self-reports (18%)
BEYOND THE PATIENT – PHASE 2

19. 21%
17%
15%22%
25%
Email
Mobile app
Patient portal
Journal
Memory / Office call / Other
19
Patients: How do you want to
share your data?
BEYOND THE PATIENT – PHASE 2
35%
65%
EMR only
Outside the EMR (email/mobile/fax)
Doctors: How do you want to
receive the data?

20. 20
Who is the first to ask about your meds?
Doctor (18%)
PA (18%)
Receptionist (5%)
Nurse/ NP (59%)
BEYOND THE PATIENT – PHASE 2

21. 59%
30%
11%
Strongly agree/Agree
Neither agree nor disagree
Strongly agree/Disagree
21
Sharing helps improve treatment
BEYOND THE PATIENT – PHASE 2
40%
37%
23%
Taking meds lowers long-term
medical costs

22. 22
-
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
18,000
1 - 19 20 - 39 40 - 59 60 - 79 80 -
100
1 - 19 20 - 39 40 - 59 60 - 79 80 -
100
1 - 19 20 - 39 40 - 59 60 - 79 80 -
100
Medical Cost Drug CostAdherence %
Source: Sokol et al., 2005
TotalCost($)
Diabetes Hypertension Hypercholesterolemia
HEALTH COSTS RELATED TO ADHERENCE

23. 23

24. 24THIS DOCUMENT IS PROPRIETARY AND CONFIDENTIAL.

25. 25

26. 26THIS DOCUMENT IS PROPRIETARY AND CONFIDENTIAL.
PROPS

27. 27
Capital Raised To Date $7 Million
Last Funding Series A, $6 Million, Jan. 2015
Timeframe Until Next Raise 6 Months
Notable Investors:
INVESTORS

28. 28THIS DOCUMENT IS PROPRIETARY AND CONFIDENTIAL.
DAYS OF USE BY CONDITION TYPE
0 20 40 60 80 100
Acute
Hybrid
Chronic

29. In the US, medication nonadherence costs more than $100 billion annually.
Medication adherence applications (apps) are a new resource to help patients
manage their medication regimens and potentially improve adherence.
However, there are hundreds of medication adherence apps making it difficult
for patients and providers to identify quality apps. In 2012, an initial study
found 160 medication adherence apps available to consumers.
• The medication adherence app market has more than doubled in the past
two years and continues to offer apps with high variability in terms of app
quality
• No app possessed all desirable author-identified features; however, several
apps were highly rated across all four domains
• Sharing this information with healthcare providers and consumers could
enable them to find a quality app that may improve their medication
adherence
• 461 medication adherence apps were initially identified across the three marketplaces
• 367 apps were available for evaluation after removing Lite/Trial versions and apps that were specific to a single medication or disease
state
• The mean initial score based on the product description was 26.7 and ranged from 23-47 (max of 68)
• Of the 100 apps eligible for testing, 19 were excluded because they failed to produce medication reminders or could not be installed by
at least one author, which included all of the Blackberry apps, leaving 81 apps for testing
• The mean user-tested score was 27 and ranged from 13-50 (max of 68)
• Compared to the initial scores, 39 (48%) user-tested scores increased, 35 (43%) user-tested scores decreased, and 7 (9%) user-
tested scores were unchanged
Navigating the Flooded Adherence App Marketplace:
Rating the Quality of Medication Adherence Apps
Catherine Renna, Rebecca Shilling, Seth Heldenbrand, PharmD, Lindsey Dayer, PharmD, BCACP, Bradley C. Martin PharmD, PhD
• Online marketplaces (iTunes, Google Play, and Blackberry App World) were
searched for medication adherence apps during June of 2014
• Inclusion criteria: English language apps capable of generating medication
reminders
• Apps limited to a single disease state or medication were excluded
• 28 author-identified desirable app features were divided into four domains
and assessed from developer descriptions
• Each feature was assigned a score based on their importance in their
respective domain (1-modest; 2-moderate; 3-high)
• Apps with Lite/Trial versions were treated as one product
• The 100 highest scoring apps were eligible for testing and were evaluated
by two authors against developer claims
• Each app was evaluated over a four day period using a standardized six
drug regimen: vitamin E once daily, diltiazem twice daily, simvastatin once
daily at bedtime, azithromycin once daily for three days, prednisone three
day taper, and alendronate once weekly
• Apps were then re-ranked based on user-tested score
CONCLUSIONS
• Development of a searchable adherence app website in order to alleviate the
frustrations of identifying quality apps in the online marketplaces
• App effectiveness could be diminished if designed without health literacy in
mind; therefore, the addition of a health literacy domain could help in
identifying apps with the highest patient usability
• To assess the smartphone medication adherence app market by evaluating
available apps based on descriptions in the marketplace and testing the
performance of the highest-scoring apps against developer claims
• Dayer L, Heldenbrand S, et al. Smartphone medication adherence apps:
potential benefits to patients and providers. J Am Pharm Assoc. 2013; 53(
2): 172– 81
RESULTSBACKGROUND
OBJECTIVES
METHODS
FUTURE DIRECTIONS
REFERENCE
#1 OF 100 APPS REVIEWED
29

30. 55%
47%
42%
39%
30%
44%
39%
36%
30%
27%26%
18%
20% 21%
16%
0%
10%
20%
30%
40%
50%
60%
1 - 19 20 - 39 40 - 59 60 - 79 80 - 100
Diabetes Hypertension Hypercholesterolemia
30
Adherence %
HospitalizationRisk
Source: Sokol et al., 2005
HOSPITALIZATIONS RELATED TO NON-ADHERENCE

31. 31
• Difference between test and control is significant at the 95% level
Patient Cohort Timeframe Test Control Absolute Lift Relative Lift
Hyperlipidemia (n=150) 6 Months 65.3% 54.7% +10.7%* +19.5%
Hypertension (n=406) 6 Months 69.7% 64.3% +5.4%* +8.4%
Diabetes (n=143) 3 Months 84.6% 76.9% +7.7%* +10.0%
IMS RETROSPECTIVE STUDY RESULTS

32. 32
Change in Systolic BP for Medisafe Stage 1 and Stage 2 Hypertensives
Avg. Improvement of 19.3 mmHg in 30 days, persists for at least 60 days
HYPERTENSION STUDY RESULTS

33. 33
56% from Stage 1 reduced their risk category
86% from Stage 2 reduced their risk category
Normal
Pre-
Stage 1
Stage 2
HYPERTENSION STUDY RESULTS

34. Scalability
HighLow
HighLow
Market Size
COMPETITION
34

35. 35
Category Leaders Traction Advantages Disadvantages
Reminder Apps Varies Address most
prevalent factor
Commoditized
Pharma(cy) Apps Huge customer base Deep pockets, direct tie
in to core business
Fragments the market
Med / Health Mgmt
Platforms
Some early market
traction (000,000)
Well funded Unfocused, relying on
extrinsic rewards
Health Ed / News Leaders in web traffic Audience of consumers
and providers
DNA is in media and
content, not tech
Pillboxes, Sorting Limited in consumer /
retail
Organization, reporting Low scalability, Limited
interactivity
Market Leader (med mgmt)
Addresses all major causes
Agnostic 3rd party
Patient centric
Caregiver / care coordination
Adherence focus
Medisafe Differentiation
COMPETITION
THIS DOCUMENT IS PROPRIETARY AND CONFIDENTIAL.